Related Experiment Video

Updated: Jul 10, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
10:02

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Methylphenidate effects on functional outcomes in the Preschoolers with Attention-Deficit/Hyperactivity Disorder

Howard B Abikoff1, Benedetto Vitiello, Mark A Riddle

  • 1New York University Child Study Center, 215 Lexington Avenue, New York, NY 10016, USA. howard.abikoff@med.nyu.edu

Journal of Child and Adolescent Psychopharmacology
|November 6, 2007
PubMed

Insights

Methylphenidate (MPH) improved some functioning in preschoolers with ADHD, particularly clinician-rated severity and teacher-rated social competence. However, parent-reported emotional status worsened slightly, suggesting a need for further research into optimal treatment strategies.

Area of Science:

  • Pediatric Psychiatry
  • Neurodevelopmental Disorders
  • Pharmacological Interventions

Background:

  • Attention Deficit/Hyperactivity Disorder (ADHD) significantly impacts preschoolers' development and daily functioning.
  • Methylphenidate (MPH) is a common stimulant medication used to manage ADHD symptoms.
  • Understanding the functional outcomes of MPH treatment in young children is crucial for optimizing care.

Purpose of the Study:

  • To evaluate the effects of methylphenidate (MPH) on functional outcomes in preschoolers diagnosed with ADHD.
  • To assess MPH's impact on social skills, classroom behavior, emotional status, and parenting stress.
  • To analyze these effects during a 4-week, double-blind, placebo-controlled trial.

Main Methods:

  • 114 preschoolers with ADHD, responsive to acute MPH, were randomized to their optimal MPH dose or placebo.
  • Assessments included clinician ratings (CGI-S), parent/teacher reports (SWAN, ECI, PSI), and social skills measures (SCS, SSRS).
  • The study design was a 4-week, double-blind, placebo-controlled trial.

Main Results:

  • Clinician-rated severity (CGI-S) and teacher-reported social competence (SCS) significantly improved with MPH.
  • Parent-reported depression and dysthymia on the ECI showed slight worsening but remained within non-clinical ranges.
  • Parent measures and teacher SWAN scores did not show significant differential improvement with MPH.

Conclusions:

  • Four weeks of MPH treatment led to improvements in specific functional areas for preschoolers with ADHD.
  • Enhanced outcomes may necessitate longer treatment durations, adjusted dosages, or combined behavioral interventions.
  • Further investigation is warranted to fully elucidate MPH's long-term functional impact and optimal therapeutic strategies.
Abstract

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol13:09

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol

Published on: April 1, 2018

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...